

<b>PATENT ASSIGNMENT COVER SHEET</b>
--------------------------------------

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5818590

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT

**CONVEYING PARTY DATA**

Name	Execution Date
ROGER JOHN GRIFFIN	09/16/2016
UNIVERSITY OF NEWCASTLE UPON TYNE	09/19/2016

**RECEIVING PARTY DATA**

<b>Name:</b>	CANCER RESEARCH TECHNOLOGY LIMITED
<b>Street Address:</b>	2 REDMAN PLACE
<b>City:</b>	LONDON
<b>State/Country:</b>	GREAT BRITAIN
<b>Postal Code:</b>	E20 1JQ

**PROPERTY NUMBERS Total: 1**

Property Type	Number
<b>Application Number:</b>	16680969

**CORRESPONDENCE DATA**

**Fax Number:** (518)452-5579

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 5184525600

**Email:** JORDEN.NEWKIRK@HRFMLAW.COM

**Correspondent Name:** HESLIN ROTHENBERG FARLEY & MESITI P.C.

**Address Line 1:** 5 COLUMBIA CIRCLE

**Address Line 4:** SELECT OR ENTER, NEW YORK 12203

<b>ATTORNEY DOCKET NUMBER:</b>	3073.179A
<b>NAME OF SUBMITTER:</b>	ERICA M. HINES
<b>SIGNATURE:</b>	/Erica M. Hines/
<b>DATE SIGNED:</b>	11/13/2019

**Total Attachments: 6**

source=3073179A Assignment Griffin and Newcastle to CRT (H1599099xD16FB)#page1.tif  
 source=3073179A Assignment Griffin and Newcastle to CRT (H1599099xD16FB)#page2.tif  
 source=3073179A Assignment Griffin and Newcastle to CRT (H1599099xD16FB)#page3.tif  
 source=3073179A Assignment Griffin and Newcastle to CRT (H1599099xD16FB)#page4.tif  
 source=3073179A Request to Update Address of Assignee (H1610265xD16FB)#page1.tif



**(1) UNIVERSITY OF NEWCASTLE UPON TYNE  
AND**

**(2) MELANIE JANE GRIFFIN  
AND**

**(3) CANCER RESEARCH TECHNOLOGY LIMITED**

---

**Patent Assignment**

---

**THIS ASSIGNMENT is made effective from 29 day of September 2015**

**BETWEEN:**

- (1) **University Of Newcastle Upon Tyne**, a charitable organisation established under the University of Durham and Newcastle upon Tyne Act 1963 whose address for service is King's Gate, Newcastle Upon Tyne, NE1 7RU, UK (the "**Institute**"); and
- (2) **Melanie Jane Griffin** of Paul O'Gorman Building, Newcastle University, Medical School, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK; and
- (3) **Cancer Research Technology Limited**, a company incorporated in England and Wales under company registration number 1626049, whose registered address is Angel Building, 407 St John Street, London, EC1V 4AD, England ("**CRT**").

**WHEREAS**

- (A) Roger John Griffin (the "**Inventor**"), whose place of work was at School of Chemistry, Bedson Building, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK, was an employee of the Institute and is an inventor of the invention (the "**Invention**") claimed in GB1517216.6 filed on 29 September 2015 (the "**Priority Application**") and which Invention arose in the course of his normal duties as an employee.
- (B) Roger John Griffin died on the 24 September 2014 and a Grant of Probate of his will was issued on the 14 November 2014 to Melanie Jane Griffin as the sole executor. Under the terms of the said will Melanie Jane Griffin is the sole beneficiary.
- (C) The Institute and Melanie Jane Griffin (the "**Assignors**") have agreed to assign to CRT all their right, title and interest in and to the Invention and the Priority Application.

**NOW IT IS HEREBY AGREED** as follows:

The headings in this Assignment are for convenience only and shall not affect its interpretation.

**1. ASSIGNMENT**

**1.1** In consideration of the agreement of CRT to pay to each of the Assignors the sum of one pound (£1), receipt of which is hereby acknowledged, the Assignors hereby assign to CRT in respect of the Priority Application:

**1.1.1** all their right, title and interest in and to the Invention and the full exclusive benefit of it;

- 1.1.2 all their right, title and interest in and to the Priority Application and the full and exclusive benefit of the Priority Application and all rights, privileges and advantages associated with the Priority Application;
  - 1.1.3 the full right to apply for and obtain patents or other similar forms of protection in respect of any part or parts of the subject-matter of the Priority Application throughout the world and the right to claim priority from the Priority Application;
  - 1.1.4 all their right title and interest in and to any patents, patent applications or other similar forms of protection in respect of the Invention pursuant to the Priority Application; and all applications and granted patents or other similar forms of protection anywhere in the world claiming priority with or from such Priority Application or based on or derived from the Priority Application including but not limited to international patent applications ('PCT Applications'), in all countries designated in such PCT Applications as filed, patent applications filed in non-PCT countries ('non-PCT applications') (hereinafter collectively referred to as "the Patents and Patent Applications"), utility model and design patents and certificates of invention and all divisionals, continuations, continuations-in-part, reissues, renewals, extensions, revalidations, registrations, inventors' certificates, petty patents, additions supplementary protection certificates or equivalent to any such patent applications and patents (together with the Priority Application the "**Patent Rights**"); and
  - 1.1.5 the right to bring proceedings for any previous infringement of the rights assigned.
- 1.2 The Assignors hereby agree with CRT that the Assignors will at the request and cost of CRT promptly provide to CRT all documents relating to the filing and prosecution of the the Patents and Patent Applications and execute, sign and do all instruments, applications, documents, acts and things that may reasonably be required by CRT to enable CRT to enjoy the full benefit of the property and rights hereby assigned and (if requested to do so by CRT) to apply for any patents or other forms of protection in respect of the Invention throughout the world and fully and effectively to assign the same to CRT or as CRT shall direct.

**2. GENERAL**


- 2.1 This Agreement shall be governed by the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the courts of England and Wales.
- 2.2 No term of this Agreement is enforceable under the Contracts (Rights of Third Parties) Act 1999 by a person who is not a party to this Agreement.

**2.3** None of the Assignors shall make any press or other public announcement concerning any aspect of this Agreement without first obtaining the agreement of CRT to the text of that announcement, such agreement not to be unreasonably withheld, conditioned or delayed.

IN WITNESS whereof the parties hereto have entered into this agreement as from the day and year above written.

For and on behalf of Cancer Research Technology  
Limited

Signature: \_\_\_\_\_  
Director/secretary




Name: P J L'Huillier  
Director, Business Management

Title: \_\_\_\_\_

Date: 23 September 2016

For and on behalf of the University of Newcastle  
Upon Tyne

Signature: \_\_\_\_\_



Name: Andrea Wright-Watkinson

Title: Head of IP + Legal

Date: 19th Sept. 2016

**Melanie Jane Griffin**

Signature: Melanie J. Griffin

Date: 16/9/16

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants:            **ASTEX THERAPEUTICS LIMITED**  
                              **CANCER RESEARCH TECHNOLOGY LIMITED**

Inventor(s):           **CHESSARI, et al.**                            Examiner:                Not Yet Assigned

Serial No.:             16/680,969                                Confirmation No.:       1002

Filing Date:            November 12, 2019                               Group Art Unit:        Not Yet Assigned

Title:                   **ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING**  
                              **ANTICANCER ACTIVITY**

To:                      Mail Stop Assignment Recordation Services  
                              Commissioner for Patents  
                              P.O. Box 1450  
                              Alexandria, VA 22313-1450

**UPDATED MAILING ADDRESS OF ASSIGNEE**

Dear Commissioner:

Applicants herein note a change of mailing address for Applicant/Assignee **CANCER RESEARCH TECHNOLOGY LIMITED** as follows:

Old Address:           **CANCER RESEARCH TECHNOLOGY LIMITED**  
                              **ANGEL BUILDING**  
                              **407 ST. JOHN STREET**  
                              **LONDON, ENGLAND EC1V 4AD**

New Address:           **CANCER RESEARCH TECHNOLOGY LIMITED**  
                              **2 REDMAN PLACE**  
                              **LONDON, ENGLAD E20 1JQ**

Should there be any questions regarding this Communication, please contact Applicants' undersigned representative.

Respectfully submitted,

*/Erica M. Hines/*

Erica M. Hines, Esq.  
Attorney for Applicants  
Registration No. 65,765

Dated: November 12, 2019  
**HESLIN ROTHENBERG FARLEY & MESITI P.C.**  
5 Columbia Circle  
Albany, New York 12203-5160  
Telephone:   (518) 452-5600  
Facsimile:   (518) 452-5579



**Change of Registered Office Address**

Company Name: **CANCER RESEARCH TECHNOLOGY LIMITED**

Company Number: **01626049**



X8FBD5MA

Received for filing in Electronic Format on the: **03/10/2019**

---

## New Address Details

New Address: **2 REDMAN PLACE  
LONDON  
ENGLAND  
E20 1JQ**

**Please Note:**

The change in the Registered Office does not take effect until the Registrar has registered this form. For 14 days, beginning with the date that a change of Registered Office is registered, a person may validly serve any documentation on the company at its previous Registered Office.

---

## Authorisation

Authenticated

This form was authorised by one of the following:

Director, Secretary, Person Authorised, Liquidator, Administrator, Administrative Receiver, Receiver, Receiver Manager, Charity Commission Receiver and Manager, CIC Manager, Judicial Factor.